Study of MK-2750 for advanced lung, pancreas, colon, esophageal, stomach, or head and neck cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests an investigational drug called MK-2750 for people with certain advanced cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers that is advanced or has spread: non-small cell lung cancer, pancreatic cancer, colorectal cancer, esophageal cancer, stomach cancer, or head and neck cancer.
- You have a tissue sample (from a previous biopsy or a new one) available for testing.
- If you have HIV, hepatitis B, or hepatitis C, your infection must be well controlled with medication.
- You have not had chemotherapy, immunotherapy, or other cancer drugs within the last 4 weeks (or 5 half-lives, whichever is shorter).
- You have not had radiation therapy within the last 2 weeks, and you do not have any radiation-related side effects that require steroids.
- You do not have active brain metastases, a history of interstitial lung disease, or other serious medical conditions that might interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, MK-2010, alone or with other treatments for people with advanced solid tumors. The goal is to learn if it is safe and effective. Participants should be in fairly good health despite their cancer.
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.